Price
No data yet.
Social Signal Score
Analyst Ratings
19 analystsRevenue
$213.28M+185.84%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Christopher David Young
- Sector
- Technology
- Industry
- Software - Application
- Employees
- 2,000
- Beta
- 0.75
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 1.97
Financials
Revenue
$213.28M+185.8%Net Income
$-46.63M-736.6%EBITDA
$33.22M+136.6%Free Cash Flow
$30.52M+1610.7%EPS (diluted)
$-0.29-613.3%Shares Outstanding (diluted)
162.09M+25.0%Operating Expenses
$126.00MCash & Debt
$217.80MReturn of Capital
$27.06MRevenue by Segment (annual)
$1.39BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $748.44M | $7.21M | $0.05 |
| 2024 | $666.78M | $-52.73M | $-0.34 |
| 2023 | $572.39M | $-13.09M | $-0.09 |
| 2022 | $491.62M | $-12.30M | $-0.08 |
| 2021 | $425.55M | $-1.48M | $-0.01 |
| 2020 | $374.67M | $-75.08M | $-0.60 |
| 2019 | $321.50M | $31.06M | $0.21 |
| 2018 | $272.40M | $-6.11M | $-0.05 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.07
- Implied price
- $1.32
- Return from $17.30
- -40.2% a year
To earn 15.0% a year on these assumptions you'd need to buy at $0.66 — -96.2% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | -50.0% | -47.7% | -45.7% | -44.0% | -42.5% |
| 3.0% | -47.4% | -45.0% | -43.0% | -41.2% | -39.6% |
| 8.0% | -44.9% | -42.3% | -40.2% | -38.3% | -36.7% |
| 13.0% | -42.3% | -39.7% | -37.4% | -35.5% | -33.7% |
| 18.0% | -39.8% | -37.0% | -34.7% | -32.6% | -30.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70-26.32%Social Signal Score
Mentions (43)
- Newsseekingalpha.com·2d ago·Positive
Vertex Pharmaceuticals: Look For Povetacicept Approval In 2 Weeks As Next Catalyst Vertex Pharmaceuticals Incorporated remains a Buy: shares look fairly valued, but durable CF cash flows and pipeline potential support long-term market outperformance. VRTX's CF franchise accounts for an estimated 60% of market value, with high-single-digit growth and patent protection supporting a decade of cash generation. Journavx offers the strongest approved non-CF opportunity, with growing prescriptions and
View source ↗ - Newsseekingalpha.com·9d ago·Neutral
Maze Therapeutics: Vertex Is Building The Road, And Maze Gets To Drive On It Maze Therapeutics, Inc. is positioned as the only APOL1 inhibitor competitor to Vertex, with strong Phase 2 data and funding into 2029. MAZE's HORIZON trial showed robust uACR reductions, especially in non-diabetic and severe FSGS patients, supporting a pivotal trial in these populations. Vertex's AMPLITUDE results and market-building efforts de-risk MAZE's path, offering regulatory precedent and commercial infrastructu
View source ↗ - Newsglobenewswire.com·12d ago·Neutral
Only One in Six Enterprises Treats Indirect Tax as a Standing Board Item KING OF PRUSSIA, Pa., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), the Decision-to-Defense™ global indirect tax and compliance company, today released the 2026 Vertex CompOps™ Index, a global study of how enterprises govern indirect tax and compliance, and how closely tax, IT, and finance work together to run it.
View source ↗ - Newszacks.com·13d ago·Positive
Here is Why Growth Investors Should Buy Vertex (VERX) Now Vertex (VERX) could produce exceptional returns because of its solid growth attributes.
View source ↗ - Newsfool.com·15d ago·Positive
Bristol Myers Squibb vs. Vertex: Which Pharma Stock Is a Better Buy for 2027? Bristol Myers Squibb is an established pharmaceutical powerhouse with a high-yield dividend and a focus on expanding its portfolio through strategic oncology alliances. Vertex Pharmaceuticals maintains a dominant position in the cystic fibrosis market while diversifying into gene editing and treatments for acute pain.
View source ↗ - Newsfool.com·17d ago·Neutral
Prediction: Vertex Pharmaceuticals Will Be 1 of the Best Biotech Stocks to Own Over the Next 5 Years Vertex Pharmaceuticals' moat in cystic fibrosis remains nearly impregnable. The company's diversification efforts are slowly ramping up, and more is to come.
View source ↗ - Newsmarketbeat.com·17d ago·Neutral
What Vertex (VERX) Said on Its Q3 Earnings Call Vertex NASDAQ: VERX raised its full-year revenue and earnings guidance after reporting third-quarter revenue growth of 11% and a nearly 50% increase in adjusted earnings before interest, taxes, depreciation and amortization, or EBITDA.
View source ↗ - Newsseekingalpha.com·17d ago·Positive
Vertex, Inc. (VERX) Q3 2026 Earnings Call Transcript Vertex, Inc. (VERX) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·18d ago·Neutral
Vertex (VERX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates While the top- and bottom-line numbers for Vertex (VERX) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
View source ↗ - Newsfxempire.com·18d ago·Neutral
Vertex Pharmaceuticals Thrives on Higher Sales and Guidance VRTX's Q3 fiscal 2027 revenue rose 12% YoY to $3.44B, driven by cystic fibrosis and new products like CASGEVY and PALSONIFY.
View source ↗ - Newszacks.com·19d ago·Neutral
Vertex Q3 Earnings Call Highlights Revenue Beat and Pipeline Expansion VRTX beats Q3 revenue estimates and raises its 2026 outlook as CF therapies and newer drugs drive growth, but acquisition costs pressure earnings.
View source ↗ - Newsmarketbeat.com·20d ago·Neutral
Vertex Pharmaceuticals Q3 Earnings Call Highlights Vertex Pharmaceuticals NASDAQ: VRTX reported third-quarter 2026 revenue growth of 12% year over year, supported by continued cystic fibrosis franchise growth and contributions from newer products including CASGEVY, JOURNAVX and PALSONIFY.
View source ↗ - Newsfool.com·20d ago·Neutral
Vertex Spends Its CF Growth on New Launches: Rapid Earnings Reaction Alyftrek is replacing Trikafta, and that switch is still growing Vertex's cystic fibrosis franchise. Heavy spending on new launches and the Crinetics deal kept profit from rising with sales.
View source ↗ - Newsglobenewswire.com·20d ago·Neutral
…ure Software, Inc. (Nasdaq: ASUR), a leading provider of cloud-based Human Capital Management software and payroll tax management solutions, and Vertex, Inc. (NASDAQ:VERX), the Decision-to-Defense™ global indirect tax and compliance company, today announced a strategic partnership designed to deliver an improved payroll tax calculation and compliance offering to the U.S. enterprise market. The partnership includes Vertex's payroll tax calculation technology with Asure's Payroll Tax Management in…
View source ↗ - Newszacks.com·26d ago·Positive
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards? VRTX is poised for a Q3 earnings beat as strong demand for Trikafta, Alyftrek's growth and rising Casgevy and Journavx sales drive expectations.
View source ↗ - Newsglobenewswire.com·27d ago·Negative
Vertex Introduces Vertex Sōl™, a Connected, AI-Powered Tax and Compliance Experience Starting with the tax decision, Vertex Sōl connects the work, evidence, and AI that tax professionals control Starting with the tax decision, Vertex Sōl connects the work, evidence, and AI that tax professionals control
View source ↗ - News247wallst.com·27d ago·Negative
The $500 Million Non-CF Factor Vertex Investors Can't Ignore on Nov. 2 Vertex Pharmaceuticals (NASDAQ:VRTX | VRTX Price Prediction) reports third-quarter results on Nov. 2. Cystic fibrosis still pays the bills, but I'll be watching whether CASGEVY and JOURNAVX stay on pace for management's $500 million non-CF revenue target.
View source ↗ - Newsfool.com·29d ago·Negative
Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change. The biotech company has grown its annual revenue by more than 600% over the past decade. Kidney disease therapy inaxaplin is seen as a possible blockbuster drug.
View source ↗ - Newsmarketbeat.com·29d ago·Positive
Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III Vertex Pharmaceuticals NASDAQ: VRTX outlined updates across its kidney disease pipeline at the American Society of Nephrology Kidney Week 2026, highlighting data for povetacicept in IgA nephropathy and inaxaplin in APOL1-mediated kidney disease, or AMKD.
View source ↗ - Newsglobenewswire.com·33d ago·Positive
Vertex AI and Data Leader Sarah Vlasic Named a 2026 Info-Tech Women Leading IT Award Winner Recognition highlights Vlasic's leadership of Vertex's enterprise AI and data transformation and her commitment to developing the next generation of women in technology Recognition highlights Vlasic's leadership of Vertex's enterprise AI and data transformation and her commitment to developing the next generation of women in technology
View source ↗ - Newsglobenewswire.com·38d ago·Neutral
Vertex to Announce Third Quarter 2026 Financial Results on Wednesday, November 4, 2026 KING OF PRUSSIA, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), the Decision-to-Defense™ global indirect tax and compliance company, today announced that it will release third quarter 2026 financial results after the market close on Wednesday, November 4, 2026.
View source ↗ - Newsfool.com·38d ago·Neutral
Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders Thanks to its most recent acquisition, Vertex now has some promising products in the field of hormone disorders. These could eventually become meaningful growth drivers for the company.
View source ↗ - Newsglobenewswire.com·38d ago·Neutral
…d Value to Customers with Vertex O Series Tax Engine for Oracle Deployed on Oracle Cloud KING OF PRUSSIA, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), the Decision-to-Defense™ global indirect tax and compliance company and an Oracle partner, today announced that its enterprise tax determination engine, Vertex O Series Tax Engine for Oracle, has achieved Oracle Validated: Oracle Cloud Infrastructure Expertise and is now available in the Oracle Mar…
View source ↗ - Newsseekingalpha.com·42d ago·Positive
Vertex Built The NaV1.8 Market, Latigo May Be The One To Profit From It Latigo Biotherapeutics is undervalued below IPO, with onzotrigine showing superior efficacy to Vertex's Journavx in acute pain. LTGO leverages Vertex's market groundwork, has pivotal-eligible Phase 2 data, and is funded into 2029, reducing near-term financing risk. Onzotrigine's Phase 3 bunionectomy trial is the key binary event; positive results could drive significant upside versus current market expectations.
View source ↗ - Newsbusinesswire.com·44d ago·Neutral
Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insu
View source ↗ - Newsfool.com·52d ago·Positive
Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? Axsome Therapeutics is delivering explosive revenue growth as it scales its commercial portfolio for central nervous system disorders. Vertex Pharmaceuticals remains a highly profitable giant with absolute dominance in cystic fibrosis and expanding reach in gene therapy.
View source ↗ - Newsglobenewswire.com·52d ago·Neutral
Vertex Appoints DataRobot CEO Debanjan Saha to Board of Directors KING OF PRUSSIA, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), the Decision-to-Defense™ global indirect tax and compliance company, today announced the appointment of Debanjan Saha to its Board of Directors, effective October 7, 2026.
View source ↗ - Newsfool.com·54d ago·Neutral
2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right. Vertex Pharmaceuticals is the leader in the cystic fibrosis market and has the intellectual property to maintain this dominance. The company has expanded into additional treatment areas and is awaiting a regulatory decision for another potential new product in the coming weeks.
View source ↗ - Newszacks.com·60d ago·Negative
Vertex Posts Positive Phase II Data on Kidney Disease Drug VRTX announces positive AMPLIFIED data for inaxaplin, while completing AMPLITUDE enrollment and targeting interim results in early 2027.
View source ↗ - Newsbenzinga.com·61d ago·Negative
Vertex Touts Encouraging Data From 'Underappreciated' Kidney Drug Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Tuesday reported data from its Phase 2b AMPLIFIED trial evaluating inaxaplin in individuals with APOL1-mediated kidney disease (AMKD).
View source ↗ - Newsmarketbeat.com·69d ago·Neutral
Vertex Pharmaceuticals Eyes Renal Growth With Key PDUFA, Pipeline Catalysts Ahead Vertex Pharmaceuticals NASDAQ: VRTX is continuing to broaden its business beyond cystic fibrosis, with its renal medicine portfolio, rare endocrine assets and cell therapies among the company's priorities, CEO and President Reshma Kewalramani said at Morgan Stanley's 24th Annual Healthcare Conference.
View source ↗ - Newsmarketbeat.com·71d ago·Neutral
Vertex Pharmaceuticals Highlights Catalyst-Rich Pipeline Beyond Cystic Fibrosis Vertex Pharmaceuticals NASDAQ: VRTX highlighted a series of upcoming clinical, regulatory and commercial catalysts across renal disease, pain management, cystic fibrosis and endocrinology during a Wells Fargo healthcare conference appearance.
View source ↗ - Newsmarketbeat.com·71d ago·Neutral
Vertex Pharmaceuticals Maps Growth Beyond CF at Cantor Conference Vertex Pharmaceuticals NASDAQ: VRTX outlined a broadening commercial and clinical strategy at the Cantor Global Healthcare Conference, highlighting its recent Crinetics acquisition, planned renal product launch efforts and upcoming pipeline milestones across kidney disease, pain, cystic fibrosis and rare endocrine disorders.
View source ↗ - Newsfxempire.com·72d ago·Positive
Strong Core Business, Raised Guidance Push Vertex Pharmaceuticals Higher Since 2008, Vertex Pharmaceuticals, Inc. (VRTX) shares have received 42 outlier institutional inflow signals and gained over 1,682%.
View source ↗ - Newsseekingalpha.com·74d ago·Positive
Vertex, Inc. (VERX) Presents at Goldman Sachs Communacopia + Technology Conference 2026 Transcript Vertex, Inc. (VERX) Presents at Goldman Sachs Communacopia + Technology Conference 2026 Transcript
View source ↗ - Newsfool.com·75d ago·Positive
Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock Vertex Pharmaceuticals' core business is rock-solid, but it is also slowly expanding into new areas. The company should see improved top-line growth over the next few years, driven by new launches.
View source ↗ - Newsfool.com·79d ago·Positive
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? Vertex Pharmaceuticals is slowly but surely expanding beyond its highly successful core therapeutic area. Regeneron has successfully rebounded after facing biosimilar competition for a key growth driver, and it boasts several attractive pipeline candidates.
View source ↗ - Newsglobenewswire.com·80d ago·Neutral
Vertex to Present at the Goldman Sachs Communacopia + Technology Conference KING OF PRUSSIA, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), the Decision-to-Defense™ global indirect tax and compliance company, today announced that Chris Young, President and Chief Executive Officer, and John Schwab, Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs Communacopia + Technology Conference on Wednesday, September 9, 2026 at 1:05 PM Pacific Time.
View source ↗ - Newsbusinesswire.com·88d ago·Neutral
Vertex to Participate in Upcoming September Investor Conferences BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in four upcoming investor conferences. Susie Lisa, Senior Vice President of Investor Relations and Manisha Pai, Executive Director of Investor Relations, will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 4:30 p.m. EDT. Susie Lisa and Manisha P
View source ↗ - Newszacks.com·88d ago·Negative
Vertex Pharmaceuticals Up 15% in a Month: How to Play the Stock Vertex's stock is up 15% in a month as strong CF sales, rising non-CF drug revenues and renal pipeline progress boost its growth story.
View source ↗ - Newsfool.com·93d ago·Neutral
Vertex Pharmaceuticals: A Biotech Cash Cow With Pipeline Upside? Explore the exciting world of Vertex Pharmaceuticals (VRTX +1.44%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
View source ↗ - Newsseekingalpha.com·100d ago·Neutral
Vertex Pharmaceuticals: I Was Wrong About Its Near-Term Prospects (Rating Upgrade) I was too cautious previously on Vertex Pharmaceuticals' prospects. Revenue from its cystic fibrosis franchise grew 10% quarter-on-quarter and 10.6% year-on-year to about $3.21 billion in Q2. On July 6, VRTX announced the acquisition of Crinetics Pharmaceuticals for about $10 billion, thereby strengthening its position in the endocrinology drugs market.
View source ↗ - Newsglobenewswire.com·101d ago·Neutral
Vertex Report: Rising Sales Tax Rates Signal a New Era of Tax Volatility KING OF PRUSSIA, Pa., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), the Decision-to-Defense™ global indirect tax and compliance company, today released its 2026 Mid-Year U.S. Sales Tax Rates and Rules Report, revealing that the combined average U.S. sales tax rate climbed for the first time in four years to reach a 10-year high of 10.1881%.
View source ↗
Earnings
Wed, Feb 10(in 3 months)
Consensus estimate $0.22 per share
Typical surprise +6.3% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$0.26 vs $0.22beat
- Mon, Aug 3$0.20 vs $0.19beat
- Thu, May 7$0.17 vs $0.16beat
- Wed, Feb 11$0.17 vs $0.17beat
- Mon, Nov 3$0.17 vs $0.17beat
- Wed, Aug 6$0.15 vs $0.14beat
Estimates and results for VERX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by VERX officers and directors.
- Bought
- $6.5m
- Sold
- $28.0m
5 trades
10 trades
- Leib Ryan Jsold
- Destefano Davidsold
- Item Second Irr. Trust Fbo Kyle R. Westphal U/a Of Jeffrey R. Westphal Dated October 5, 2001bought
- Young Christopher Davidbought
- Andersen Eric C.bought
- Westphal Jeffreybought
- Westphal Jeffreybought
- Item Second Irr. Trust Fbo Anne Marie Westphal U/a Of Jeffrey R. Westphal Dated October 5, 2001sold
85 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in VERX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
